Adial Pharmaceuticals CEO Cary Claiborne set to depart after Sept. 17 annual meeting; CDO Matthew Davidson slated to succeed

Reuters2026/08/13 21:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Adial Pharmaceuticals flagged a potential leadership reshuffle tied to a shareholder vote at its Sept. 17, 2026 annual meeting.
CEO Cary Claiborne is expected to be removed promptly following the meeting if the proposals pass.
Matthew Davidson, chief development officer and a board member, is slated to become president and CEO if the vote clears.
CFO Vinay Shah is also expected to be removed promptly following the meeting if the proposals pass.
Board turnover is anticipated, including resignations of legacy directors, though no final decisions have been made.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-089270), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Adial Pharmaceuticals CEO Cary Claiborne set to depart after Sept. 17 annual meeting; CDO Matthew Davidson slated to succeed

You may also like

Crypto prices